Biotech Breakthroughs
Invest in

Biotech Breakthroughs

36.8%
3.2%
2.6%

Feeling Better About Biotech

The next big cure for a complex, scary disease is unlikely to come from old-school pharma. It’s likely coming from biotech. Scientists, investors, and patients are all banking on the $93 billion biotech industry.[1] It’s outpaced Big Pharma in finding treatments for cancer, AIDS, multiple sclerosis, and other diseases. The FDA approved 43 drugs in 2012, a 20% jump from the previous year.[4] Big Pharma has responded by snapping up promising biotech and smaller pharmaceutical companies, at lofty valuations, with premiums for several public companies in excess of 50%.[2] In fact, 2013 was a big year for the biotech industry, with $29B in M&A deals through the 1st half of 2013.[3] This motif includes only biotech companies with at least two years of cash flow to help screen out companies at greater risk of losing money. See more
36.8%
3.2%
2.6%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Biotech Breakthroughs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
29.4% Cancer 38.6%
16.3% Amgen Inc AMGN 31.8%
10.0% Celgene Corp. CELG 53.9%
1.2% Seattle Genetics Inc. SGEN 40.8%
1.1% Spectrum Pharmaceuticals Inc. SPPI 0.6%
0.8% Medivation Inc. MDVN 34.7%
19.8% Autoimmune Disorders 68.7%
9.4% Biogen Inc BIIB 10.8%
5.8% BioMarin Pharmaceutical Inc. BMRN 141.6%
1.9% Incyte Corp. INCY 130.3%
1.5% Xencor Inc XNCR 148.5%
1.2% ACADIA Pharmaceuticals Inc. ACAD 140.6%
18.4% Infectious Diseases 34.7%
14.7% Gilead Sciences Inc. GILD 23.8%
2.7% Opko Health Inc. OPK 89.0%
1.0% Emergent Biosolutions Inc. EBS 47.3%
18.3% Other Diseases 48.0%
5.1% Alexion Pharmaceuticals Inc. ALXN 23.5%
5.1% Regeneron Pharmaceuticals Inc. REGN 79.3%
3.5% Vertex Pharmaceuticals Incorporated VRTX 31.3%
1.5% United Therapeutics Corporation UTHR 86.3%
1.2% The Medicines Company MDCO 44.2%
1.1% Alkermes plc ALKS 53.8%
1.0% Acorda Therapeutics Inc. ACOR 15.3%
14.1% Research & Diagnostics 23.4%
4.2% Illumina Inc. ILMN 33.1%
4.2% Quintiles Transnational Holdings Q 36.8%
3.2% Qiagen N.V. QGEN 10.5%
1.7% Bio-Techne Corp TECH --
0.7% Abaxis Inc. ABAX 3.7%